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Ubiquitin signalling is a fundamental eukaryotic regulatory system, controlling diverse
cellular functions. A cascade of E1, E2, and E3 enzymes is required for assembly of
distinct signals, whereas an array of deubiquitinases and ubiquitin-binding modules edit,
remove, and translate the signals. In the centre of this cascade sits the E2-conjugating
enzyme, relaying activated ubiquitin from the E1 activating enzyme to the substrate,
usually via an E3 ubiquitin ligase. Many disease states are associated with dysfunction of
ubiquitin signalling, with the E3s being a particular focus. However, recent evidence
demonstrates that mutations or impairment of the E2s can lead to severe disease states,
including chromosome instability syndromes, cancer predisposition, and immunological
disorders. Given their relevance to diseases, E2s may represent an important class of
therapeutic targets. In the present study, we review the current understanding of the
mechanism of this important family of enzymes, and the role of selected E2s in disease.
Introduction
Protein ubiquitination is a reversible post-translational modiﬁcation that modulates a variety of
homeostatic processes in eukaryotic cells. The modiﬁcation typically involves the sequential action of
activating enzymes (E1s), conjugating enzymes (E2s), and ligase enzymes (E3s), resulting in an iso-
peptide link between the C-terminus of ubiquitin (Ub) and a speciﬁc lysine on a target protein [1].
Brieﬂy, E1s activate the C-terminus of ubiquitin in an ATP/Mg2+-dependent manner and load ubiqui-
tin onto a conserved catalytic cysteine within E2s (denoted as E2∼Ub). Subsequently, hundreds of dif-
ferent E3s can then associate with one or more E2∼Ub to catalyze the ubiquitination of substrate
targets (Figure 1A). The surface of ubiquitin itself presents several conserved functional patches, for
example, the Ile44-hydrophobic patch (Leu8/Ile44/His68/Val70), which sustains crucial non-covalent
interactions during ubiquitination as well as in signalling [2,3]. In addition, any of the seven surface
lysines, or the N-terminus of ubiquitin, supports further building of ubiquitin chains that adopt
distinct topologies [4]. Ubiquitin-binding domains are present within numerous proteins and can
discriminate the different ubiquitin chain types, thereby facilitating signal cascades and protein networks
[5]. Post-modiﬁcation, enzymes called deubiquitinating enzymes (DUBs) can alter or erase the ubiqui-
tin signals, thus modulating the event [6] (Figure 1A). Ubiquitin-like proteins (Ubls), such as SUMO
(small ubiquitin-like modiﬁer) and NEDD8 (neural precursor cell expressed developmentally down-
regulated protein 8), also take part in post-translation modiﬁcations. These have a similar, but smaller,
cohort of proteins that regulate the modiﬁcation and have been reviewed elsewhere [7,8]. An intricate
balance between E3 ligase and DUB activities regulates the speciﬁcity of the ubiquitin signal.
Unsurprisingly, deregulation of these enzymes has been linked to several cancers and neurodegenera-
tive diseases [9–12]. In addition to the large E3 and DUB classes, recent studies illustrate how E2s are
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more than just intermediaries of the ubiquitin pathway, but have multifaceted roles in human physiology and
pathology. What follows is a review of our current mechanistic understanding of E2s, and the role of selected
E2s in disease.
Structure–function overview of the E2 fold
Humans have around 35 ubiquitin E2 family members, all sharing a core ubiquitin conjugation (UBC) domain
that spans roughly 150 residues. Previously, E2s were classiﬁed by their UBC domain extensions; class I E2s
have only the core domain, classes II and III have N- or C-terminal extensions respectively, and class IV are
extended at both ends [13]. The extensions in the majority of classes II and III E2s are largely conserved, but
lack secondary structure; they inﬂuence localization, E1/E3 interactions, or the ubiquitination event. Class IV
enzymes, such as UBE2O and BIRC6, are signiﬁcantly larger (>1200 residues) and are likely to be multidomain
proteins. Currently, the HUGO Gene Nomenclature Committee has formally categorized mammalian E2s using
the syntax UBE2Xn, where X and n denote a letter and number, respectively (http://www.genenames.org/
cgi-bin/genefamilies/set/102). UBC folds (Figure 1B) contain an N-terminal helix (α1), a four-stranded
β-meander (β1–4), a short 310-helix that leads into the central ‘cross-over’ helix (α2), and two C-terminal
helices (α3 and 4) [14,15]. The E2 catalytic cleft is located in a shallow groove with the active-site cysteine
preceding the 310-helix. The catalytic cysteine is structurally supported by a tri-peptide His-Pro-Asn motif that
is a conserved UBC fold feature [16,17]. Certain ubiquitin E2s vary slightly in the tri-peptide sequence, for
example His-Pro-His in UBE2W, whereas others like the UBE2J and UBE2Q family completely lack the motif.
Figure 1. Ubiquitin pathway and the E2 fold.
(A) Overview of the Ub pathway and the enzymes involved at each step: activation (E1), conjugation (E2), ligation (E3), and
deubiquitination (DUB). The E1 mediates ubiquitin activation in an energy-consuming step. The ubiquitin thioester is then
transferred onto a catalytic cysteine of the E2 enzyme. RING-type E3s form a non-covalent complex with the E2∼Ub thioester
intermediate or, alternatively, ubiquitin is transferred to catalytic sites of HECT and RBR-type E3 ligases. The E3 enzymes
ultimately catalyze ubiquitination of a substrate lysine. Ubiquitin signals can also be extended to form polyubiquitin chains.
Finally, DUBs catalyze the removal of ubiquitin. (B) Ribbon diagram of UBE2D2 (PDB 2ESK) as a representative of the UBC
fold conserved among ubiquitin E2s. Secondary structure elements and the termini of the domain are indicated. Also depicted
is the location of the active-site cysteine within the catalytic cleft (yellow oval), the E3-binding region (blue oval), the cross-over
helix that stabilizes ‘closed’ conformers of the E2∼Ub thioester intermediate and location of the E2 backside-binding surface
(red dashed line).
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Nevertheless, the variations do not abolish the ubiquitin conjugation activity in these E2s [18]. In contrast, the
UBE2V family is devoid of both the catalytic cysteine and the His-Pro-Asn motif, and these proteins function
as cofactors for the UBE2N enzyme. Also present in the catalytic cleft is a crucial, negatively charged, residue
(typically Asp) in the α3–α4 loop that aligns the incoming substrate lysine towards the E2 catalytic cysteine
[19]. Alternatively, in certain E2s, for example UBE2A, a neutral serine is present at the analogous position and
phosphorylation of this residue can regulate the E2 enzyme function [20–23].
Ubiquitin can be activated by two distinct E1s: UBA1 and UBA6, with UBA1 capable of loading ubiquitin
on the majority of E2s [24–26]. Structure–function studies of ubiquitin and Ubl E1s have uncovered details of
the activation process and are reviewed elsewhere [27,28]. Interestingly, in mammalian cell lines, certain E2s
(for example, the UBE2R family) are constitutively loaded with ubiquitin [25]. Structures of E2∼Ub thioester
mimics reﬂect the dynamic conformations adopted by ubiquitin relative to the E2 [29–31]. In particular, the
UBE2N∼Ub mimic resembles a compact ‘closed’ conformation more frequently than does a UBE2D3∼Ub
mimic. The different conformers can be indicative of the ubiquitination potential of the E2. A closed E2∼Ub
conformation is stabilized by interactions between the Ub Ile44-hydrophobic patch and conserved hydrophobic
residues on the E2 cross-over helix. In UBE2S, UBE2R1, and UBE2G2, this closed conformation promotes efﬁ-
cient ubiquitin discharge, as well as E3-independent ubiquitin chain formation [32,33]. In addition, some E2s
are capable of building linkage-speciﬁc polyubiquitin chains that involve additional interactions between the E2
and the acceptor ubiquitin surface surrounding the target lysine. In case of UBE2K [34,35], residues around the
UBC catalytic cleft position the Lys48 surface of the acceptor ubiquitin, whereas C-terminal helices of UBE2S
[33,36] orient the Lys-11 surface of the incoming ubiquitin. In contrast, the Lys63-speciﬁc UBE2N relies on an
inactive E2 partner UBE2V1/2 to orientate the acceptor ubiquitin surface [37]. In the case of UBE2G2, homo-
dimerization of E2∼Ub intermediate facilitates both donor and acceptor ubiquitin surfaces required for catalysis
and results in assembly of Lys48-linked ubiquitin chains on E2 catalytic cysteine [38–40]. Other Lys48-speciﬁc
E2s, including the UBE2G and UBE2R families [41–43], have insertions of variable lengths near the catalytic
cleft. These facilitate linkage-speciﬁc products via different modes and have been reviewed elsewhere [44]. In
the majority of cases, linkage-speciﬁc E2s extend previously monoubiquitinated substrates. This enables sub-
strate polyubiquitination to be delineated into distinct events, that is ubiquitin chain initiation followed by
elongation [45–47]. Initial ubiquitin conjugation, or lysine-speciﬁc monoubiquitination on substrates, almost
always requires an E3. A contrasting example is the UBE2E family where disordered N-terminal extensions
impede polyubiquitination events [48]. Remarkably, this E2 family mediates an E3-independent, site-speciﬁc
monoubiquitination of the DNA methyltransferase SETDB1 and, consequently, stimulates the methyltransferase
activity [49]. Furthermore, direct cross-talk between the DUB enzyme OTUB1 and several E2s, including the
UBE2E family, is observed during DNA damage-associated ubiquitination [50]. Structural analyses reveal how
ubiquitin from an E2∼Ub intermediate occupies the proximal ubiquitin-binding site of OTUB1, while free
ubiquitin binds the distal site. The ternary E2∼Ub/OTUB1/Ub complex inhibits both ubiquitin discharge from
the E2∼Ub intermediate and the DUB activity of OTUB1 [51,52].
Towards the N-terminus of the UBC fold are partially overlapping surfaces (α1, the β2–β3 loop, and the
310-to-α2 loop) involved in interactions with both the E1 and E3 (Figure 1B). This overlap ensures that the
E1–E2- and E2–E3-binding events are mutually exclusive during ubiquitin transfer, thus regulating the ﬂow of
the pathway [53,54]. Interactions of E2–E3 are usually weak and transient in nature, with dissociation constants
in the high micromolar range. Conserved E2 residues that support the canonical E2–E3 interaction include polar
residues in the N-terminal helix (typically Arg/Lys) and hydrophobic residues in the β2–β3 loop (typically Phe)
and the 310-to-α2 loop (typically Pro and Ala). Structures of the UBE2D family in complex with different E3s
reveal how the E2 surface offers plasticity in the E2–E3 interaction [55–57]. Interestingly, E3 binding does not
induce major conformational changes within the E2 UBC fold. Given that the E3-binding site is remote from
the E2 catalytic cleft, the underlying mechanism forming a productive E2–E3 complex was not immediately
clear. E3 ligases are broadly classiﬁed by how they catalyze the ubiquitination event. Brieﬂy, really interesting
new gene (RING)/U-box E3s (reviewed in ref. [58]) mediate direct transfer of ubiquitin from E2∼Ub to the
target substrate, whereas the homologous to the E6-AP C-terminus (HECT) and RBR E3s (reviewed in refs
[59,60]) form an additional ubiquitin thioester intermediate on a conserved catalytic cysteine (E3∼Ub) prior to
substrate modiﬁcation (Figure 1A). This distinction results in RING E3s being dependent on the partner E2 for
regulating the ubiquitin product type, whereas HECT and RBR E3s can potentially overrule any linkage-speciﬁc
bias. The different modes of ubiquitin transfer suggested that a productive E2∼Ub–E3 complex might differ
depending on the type of E3 involved. Recent structural and biochemical analyses of the UBE2D family have
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revealed that HECT/RBR E3s do not require a closed E2∼Ub conformation to catalyze ubiquitination [61–64].
In contrast, RING/U-box E3s promote a closed E2∼Ub conformation, and mutations in the E2 cross-over helix
that destabilize this result in the loss of ubiquitination [19,65,66]. Structures of an E2∼Ub mimic in complex
with RING/U-box E3s also reveal critical contacts between E3s and ubiquitin that inﬂuence ubiquitination.
First, a conserved E3 residue, typically Arg, makes connections with the Ile36 hydrophobic patch of ubiquitin as
well as with the E2 main chain. These connections are essential for all RING/U-box-mediated ubiquitination;
consequently, this residue has been denoted the allosteric ‘linchpin’. Second, the ubiquitin is further buttressed
by contacts with homo-/hetero-dimeric partners of the RING domains, or by non-RING elements [19,65,66].
Taken together, these studies demonstrate how RING domain E3s, previously considered as mere molecular
scaffolds, can actively inﬂuence the E2∼Ub intermediate for ubiquitination. Substrate binding and speciﬁcity,
fundamentally an E3 attribute, can also involve direct E2–substrate interactions, as seen with the PCGF4 (poly-
comb group RING ﬁnger)/RING1B–UBE2D3 complex bound to the nucleosome target [67]. However, how the
E2∼Ub/E3 modules interact with their non-ubiquitin-based target substrates is largely unexplored.
An interaction surface of increasing interest is the ‘E2 backside’ located on the β-meander, distal to the cata-
lytic cleft (Figure 1B). In the UBE2D family, this surface supports non-covalent ubiquitin interactions that
stimulate processivity of the E2 enzyme [68,69]. Several RING E3s also harbour ancillary E2 backside-binding
regions that induce different allosteric effects, such as stabilization of the canonical RING–E2 interface, E2∼Ub
charging, and processive ubiquitination [70–74]. Interestingly, in certain E2s, the backside interaction with E3s
can regulate the type of ubiquitin signal generated on substrates [75,76]. Currently, functional roles for the E2
backside surface are observed in a quarter of all ubiquitin E2s and are predominantly coupled with RING E3s.
Given the versatility of this surface, future work will undoubtedly reveal additional mechanisms that utilize the
E2 backside to regulate ubiquitination.
Our current understanding of the mechanisms of E2 action is derived primarily from the extensively studied
UBE2D family. However, there are 35 E2s, and an increasing number of them are associated with pathologies
and diseases. Therefore, it is not surprising that there is a much greater diversity of action of E2 function than
originally expected. Below, we discus UBE2T and UBE2L3 as speciﬁc examples of disease-associated E2s and
describe our current understanding of their modes of action.
UBE2T (FANCT), the E2 enzyme in the Fanconi anaemia
pathway
The Fanconi anaemia ubiquitin signalling module
An example of the importance of E2 function in disease is the role of UBE2T in the Fanconi anaemia
syndrome (FA). The FA DNA repair pathway has become a paradigm for the physiological importance of
ubiquitin signalling in coordination of DNA repair pathways and the maintenance of genome stability. In the late
1930s, the Swiss paediatrician Guido Fanconi reported a case of three brothers who all presented with develop-
mental birth defects and eventually died of conditions reminiscent of aplastic anaemia [77]. The syndrome,
now known as Fanconi anaemia, was recognized as a rare genetic disorder affecting bone marrow function and
haematopoiesis. The combined efforts of many disciplines, ranging from paediatric haematology to biochemis-
try, determined the syndrome’s molecular defects and uncovered the molecules and mechanism of a complex
pathway that is dedicated to repairing DNA interstrand cross-links (ICLs). ICLs are induced after treatment
with cross-linking agents such as mitomycin C (MMC) and cisplatin, as well as endogenously by metabolic
by-products, most importantly reactive aldehydes. Pioneering work by Patel and colleagues provided compel-
ling evidence of the interplay between aldehyde metabolism and the FA pathway [78–81]. Experiments carried
out in mice revealed that increased aldehyde toxicity could trigger bone marrow failure, haematopoietic stem
cell depletion, and the development of acute lymphoblastic leukaemia in FA-deﬁcient mice. These defects
indeed resemble the key phenotypes of FA patients, and it suggests that the FA pathway has an essential func-
tion in neutralizing aldehyde-induced damage in humans.
To date, 20 genes are associated with FA. These genes form two major classes based on their hierarchy and
function within the FA pathway (Figure 2). The class I proteins FANCA, -B, -C, -D2, -E, -F, -G, -I, -L, -M, and
UBE2T together with the FA-associated proteins (FAAP10, FAAP16, FAAP20, FAAP24, and FAAP100) com-
prise an ‘upstream’ ubiquitin signalling module. This group co-ordinates ‘downstream’ ICL repair by the class
II proteins that include the nuclease scaffold protein SLX4 (FANCP), the structure-speciﬁc nuclease XPF
(FANCQ), and factors that are involved in homologous recombination repair: breast cancer gene 2 (BRCA2;
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FANCD1); PALB2 (FANCN); RAD51C (FANCO); RAD51 (FANCR); XRCC2 (FANCU); BRCA1 (FANCS);
and FANCJ (BRIP1). The FA genes have been discussed in detail in several excellent reviews [82–85]; hence,
we will focus on insights into the FA ubiquitin signalling module, in particular the E2-conjugating enzyme
UBE2T.
The ﬁrst evidence of an ubiquitin signalling module in FA came from the discovery of FANCD2 and its
DNA damage-induced monoubiquitination [86]. Monoubiquitinated FANCD2 accumulates on chromatin,
forming discrete foci at sites of DNA lesions, co-localizing with DNA repair factors. Any defects in FANCD2
monoubiquitination are as severe as FANCD2 loss-of-function mutations and result in hypersensitivity to
Figure 2. The Fanconi anaemia pathway.
The FA pathway comprising 20 proteins is grouped into two classes: class I deﬁnes an upstream ubiquitin signalling module,
and class II consists of downstream DNA repair proteins. The FA core complex is activated by stalled replication forks and
co-operates with the E2-conjugating enzyme UBE2T (T) to monoubiquitinate the heterodimer FANCI–FANCD2 (I–D2). The RING
E3 ligase FANCL (L) is the catalytic subunit, with associated FANCB (B) and FAAP-100 (F-100). Recruitment to stalled forks is
mediated by FANCM (M), FAAP-10, -16, and -24. Monoubiquitinated I–D2 then promotes DNA repair by coordinating TLS
(translesion synthesis) polymerase, nucleases, and HR-dependent pathways.
© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3405
Biochemical Journal (2016) 473 3401–3419
DOI: 10.1042/BCJ20160028
ICL-inducing agents and elevated frequency of chromosomal abnormalities. Thus, it is thought that monoubi-
quitination is a key step in the signal transduction cascade of the FA pathway. Intriguingly, FANCD2 and the
structurally related FA protein FANCI form a stable heterodimer FANCI–FANCD2 (I–D2), and FANCI is the
second known substrate for targeted monoubiquitination in the FA pathway [87–89]. Site-speciﬁc monoubiqui-
tination of the I–D2 complex on conserved lysine residues (FANCILys523 and FANCD2Lys561 in humans) is
mediated by an E3 ubiquitin ligase, known as the FA core complex.
The FA core complex, ﬁrst biochemically isolated by Meetei and colleagues, comprises 7 FA gene products
FANCA, -B, -C, -E, -F, -G, -L, and the FA-associated proteins FAAP20 and FAAP100 [90–93]. In addition, the
core complex associates with the DNA translocase FANCM and FANCM-associated factors FAAP10, -16, and
-24 [94–98] and is thought to form a platform to recruit the FA core complex to damaged chromatin [96–98]
(Figure 2). Within the FA complex, FANCL is the catalytic RING E3 subunit, and together with FANCB
and FAAP100 constitute a minimal E3 module essential for I–D2 monoubiquitination in vertebrate cells
[93,99–103].
The identiﬁcation of the cognate E2-conjugating enzyme for FANCL was the last missing piece in the FA
ubiquitin signalling module, as it is currently understood. Using a classical yeast two-hybrid approach,
Machida et al. [104] found FANCL to be the predominant interaction partner of UBE2T. RNAi-mediated
knockdown of UBE2T in human cells, or deletion of UBE2T in avian DT40 cells, abolished monoubiquitina-
tion of FANCD2, suggesting that UBE2T is likely the cognate E2 for FANCL in the catalysis of FANCD2
monoubiquitination [99,104]. This notion was further supported by in vitro reconstitution assays, showing that
UBE2T and FANCL are necessary and sufﬁcient to monoubiquitinate FANCD2 [100].
The UBE2T enzyme consists of a core UBC fold followed by a C-terminal extension (∼40 residues). The
extension is largely unstructured, is poorly conserved and has negligible effect in FANCL-mediated FANCD2
monoubiquitination in vitro (Arno Alpi and Helen Walden, unpublished observations). A conserved lysine
(Lys 91) near the UBE2T catalytic cleft is constitutively monoubiquitinated in vivo and has been proposed to
negatively regulate the E2 [104]. Interestingly, UBE2T has unusually strong afﬁnity for the FANCL RING
domain (∼450 nM Kd) [103]. Structural characterization of the FANCL RING–UBE2T pair reveals an interface
area (∼700 Å2) that extends beyond the generic E3–E2 interface (typical area — 450 to 600 Å2), as well as
several features that enable selective interaction for this E3–E2 pair [105]. In particular, an extended hydropho-
bic interface involves Tyr311 of FANCL anchored within an UBE2T pocket made up of Arg6, Arg9, and
Asn103 side chains. This residue is highly variable in other RINGs and typically does not participate in the
canonical RING–E2 interface. Furthermore, the β2–β3 loop of UBE2T bears a unique basic residue that forms
a salt bridge with Glu340 of FANCL. This residue, Arg60 in UBE2T, is predominantly acidic (Asp/Glu) in
other ubiquitin E2s and serves as a positive selector for the FANCL RING–UBE2T pairing.
Large-scale E2–E3 interaction studies propose interactions for UBE2T with at least 15 other E3s
[18,106–108]. Notably, UBE2T is functional with a limited set of HECT E3s and primarily supports multi-
monoubiquitination. However, the proposed UBE2T-binding RING E3s are poorly conserved with the FANCL
RING domain; only ﬁve of them could possibly support a weak interaction, if any, with the β2–β3 loop in
UBE2T. Experimental evidence for the E3s ARIH2 and RING ﬁnger 4 (RNF4) shows no signiﬁcant ubiquitina-
tion products with UBE2T [109,110], while reports on a possible UBE2T–BRCA1 RING E3 pair are conﬂicting
[111–113]. Nevertheless, FANCL was able to exclusively complex with UBE2T when presented with a group of
different E2s and only the cognate E2–E3 pair resulted in the site-speciﬁc monoubiquitination of FANCD2 in
vitro [105]. The speciﬁc and stable FANCL–UBE2T interaction offers insights into how a monoubiquitination
event is regulated. As an overlapping UBE2T surface is required for both ubiquitin loading from the E1 and
ofﬂoading via the E3, the low UBE2T off-rate could limit ubiquitin reloading, and thus curb incessant ubiquiti-
nation. However, we still do not completely understand how the FA core complex selects the precise lysine on
I–D2 for ubiquitination. In addition, the allosteric ‘linchpin’ residue (typically Arg) required for all RING/
U-box-mediated ubiquitination events is absent from FANCL (Ser363) [62]. Future structures of FANCL and/
or the FA core complex bound to an UBE2T∼Ub intermediate and its substrate will ultimately reveal the deter-
minants of this exquisitely speciﬁc ubiquitin signal.
UBE2T is a bona ﬁde FA gene
Almost a decade after the discovery of UBE2T in the FA pathway, three unrelated individuals (PNGS-252,
PNGS-255, and 100166/1) diagnosed with FA have been described carrying biallelic mutations in the UBE2T
gene locus [114–116]. Both PNGS-252 and PNGS-255 patients displayed FA-typical phenotypes including
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congenital malformations, haematological abnormalities, and high levels of chromosomal abnormalities that
allowed a clear diagnosis. In contrast, 100166/1 was born with developmental abnormalities, but had normal
bone marrow and blood counts that are atypical for FA. Despite this, he was eventually diagnosed with FA
based on a diepoxybutane analysis revealing high frequencies of DEB(diepoxybutane)-induced chromosomal
breakages in haematopoietic cells.
Genome analysis for patient PNGS-252 revealed a maternal c.4C>G missense alteration resulting in the
Gln2Glu amino acid substitution and a paternal 23 kb deletion across the UBE2T locus (Figure 3A,B) [114].
The Gln2 residue in helix1 of UBE2T is not an integral part of the UBE2T–FANCL interaction surface.
Figure 3. Schematic overview of identiﬁed UBE2T gene alterations in FA patients.
(A) Genomic locus of UBE2T with intron/exon boundaries. Start codon in exon 2, stop codon in exon 7, and AluY repeats (red
boxes) are indicated. UBE2T encodes a 197 aa protein with catalytic Cys86 in the UBC fold (dark blue). (B) Maternal missense
mutation identiﬁed in patient PNGS-252 resulting in Gln2 to Glu2 amino acid substitution. (C) The c.180+5G>A splice donor
site, identiﬁed in patient PNGS-255, initiating a frame shift and premature stop codon resulting in a truncated UBE2T protein.
Genome alterations identiﬁed patient 100166/1 showing the paternal AluY-mediated deletion (D) and maternal AluY-mediated
duplication (E). The maternal allele encodes an mRNA for a shorter UBE2T protein with a functional UBC fold.
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However, the Gln2Glu mutation binds less well to FANCL and reduces FANCD2 monoubiquitination by
UBE2T–FANCL in vitro. In agreement with this, ﬁbroblasts derived from PNGS-252-expressing mutant
UBE2T (Gln2Glu) are defective in ICL-induced FANCD2 monoubiquitination and display MMC hypersensi-
tivity. Individual PNGS-255 had two allelic alterations; the c.4C>G mutation as found in PNGS-252 and, in
addition, a c.180+5G>A splice donor site mutation [114]. This latter initiates a frame shift and premature stop
codon resulting in a truncated UBE2T protein with a non-functional UBC domain (Figure 3B,C). Both alleles
are considered to cause loss of function. The identiﬁcation of the genome alterations in patient 100166/1 was
challenging, as standard sequencing strategies including capillary Sanger and whole exome sequencing did not
initially reveal any pathogenic mutations. Ultimately, two large AluY-mediated genome rearrangements were
identiﬁed [115,116]. The patient inherited from the father a large intragenic deletion in UBE2T resulting from
a recombination event between two AluY repeats, creating a new intron between exon 1 and 7. No functional
protein is predicted to be expressed as the start codon resides in exon 2 (Figure 3D). Surprisingly, the same
AluY repeats appeared to have initiated a recombination in the maternal allele that resulted in the large
genomic duplication between these AluY repeats. The maternal allele encodes an mRNA for a truncated, but
functional, UBE2T protein. However, the transcript can be detected only at low levels and is degraded by
nonsense-mediated mRNA decay due to a premature stop codon (Figure 3E) [116]. Intriguingly, the maternal
duplication of exons 2–6 seems to be reverted in the haematopoietic system of the patient and regenerated a
wild-type allele, thus explaining that the normal blood counts observed in the patient were due to somatic
mosaicism. Despite the fact that AluY repeats are apparently prone to rearrangements in the UBE2T genomic
locus, further analysis of genomic DNA from normal individuals from Sicily (parents of patient 100166/1 are
of Italian origin with ancestors from Sicily), Northern Italy, and Germany did, however, reveal extremely low
frequencies of either AluY-mediated deletions or duplications of UBE2T exons 2–6 [116]. So far, all identiﬁed
pathogenic alterations of UBE2T are likely loss-of-function alleles and the deﬁciency of UBE2T protein is asso-
ciated with FA. Consequently, 10 years after the discovery of UBE2T protein function, UBE2T is now recog-
nized as a bona ﬁde FA gene and is alternatively named FANCT.
The speciﬁc and selective interaction of UBE2T with FANCL, as well as the typical FA-associated pathologies
observed in UBE2T-deﬁcient patients, suggests that UBE2T’s primary function is dedicated to monoubiquiti-
nate I–D2 in the FA DNA repair pathway. However, there is some evidence that UBE2T might be associated
with ubiquitin signalling pathways other than FA. In contrast with FA core complex-deﬁcient cells (including
FANCL deﬁciency), UBE2T deletion in the avian cell line DT40 (a lymphoblastoid cell) caused hypersensitivity
to UV light and cells are less efﬁcient in removing genotoxic cyclobutane pyrimidine photoadducts [117].
Further somatic genetic analysis revealed a genetic link between UBE2T and the nucleotide excision repair gene
XPA, suggesting an UBE2T-mediated signalling pathway required for efﬁcient nucleotide excision repair of
certain UV lesions. However, the putative E3 ligase and ubiquitin-targeted substrates remain to be identiﬁed
and are aims for future investigations.
As a historical note, initial evidence suggested UBE2W as an alternative E2 that can associate and function
with FANCL to monoubiquitinate FANCD2 [100,118]. However, recent discoveries addressing the genetics and
distinct catalytic features of UBE2W argue against a direct function of the E2 in FA and DNA repair pathways.
UBE2W contains non-canonical structural characteristics that catalyze monoubiquitin ligation to α-amino
termini by favouring the recognition of substrates with intrinsically disordered N-termini rather than structured
epitopes [119]. Thus, the observed monoubiquitination of FANCD2 mediated by UBE2W–FANCL in vitro is
likely to be an N-terminal ligation and does not recapitulate the lysine site-speciﬁc monoubiquitination by
UBE2T–FANCL. In agreement with this, deletion of UBE2W in human, mouse, and avian cells does not
render them hypersensitive to any tested genotoxins, including ICL-inducing agents [101,120,121], nor is DNA
damage-induced FANCD2 monoubiquitination affected [121]. UBE2W-deﬁcient mice are susceptible to early
postnatal lethality, show abnormal epidermal differentiation in the skin, and defective immune and male repro-
ductive systems, but none of these pathologies are indicative for FA [120]. Cumulatively, the requirement of
UBE2W in the DNA damage response is not essential, but might be part of a more complex regulatory
network. Recent work reveals that UBE2W can functionally interact with the RING-type E3 RNF4 [110],
which was shown to be essential for DNA double-strand break repair by both homologous recombination and
non-homologous end-joining pathways [122,123]. By employing UBE2W, RNF4 is capable of promoting
N-terminal monoubiquitination of SUMO chains in vitro [110]. However, genetic analysis reveals that simul-
taneous deletion of UBE2W in RNF4-deﬁcient cells suppresses RNF4-associated DNA repair defects, suggesting
3408 © 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Biochemical Journal (2016) 473 3401–3419
DOI: 10.1042/BCJ20160028
that UBE2W and RNF4 function in different pathways [121]. To date, the biological function of UBE2W is far
from being well understood and will be the subject for future investigations.
UBE2T: potential oncogenic and tumour suppressor function in
carcinogenesis
FA patients are highly susceptible to developing some form of malignancy throughout their lives with an
observed-to-expected ratio of 48 over all cancers including leukaemia and solid tumours [124]. The majority of
described leukaemias are acute myeloid leukaemia (AML), and the most common solid tumours are head and
neck squamous cell carcinomas (HNSCC) [124]. FA patients deﬁcient in genes of the homologous recombin-
ation repair pathway (FANCD1, FANCN, and FANCJ) are particularly prone to breast cancer [125–127],
whereas FANCO mutations are associated with increased susceptibility to ovarian cancer [128,129]. So far, an
accurate assessment of cancer predisposition linked with UBE2T loss of function is hampered by the limited
number of affected patients. Patient PNGS-252 developed severe pancytopenia at age 13, successfully received
bone marrow transplantation (BMT), and remains alive in haematological remission since then. Patient
PNGS-255 developed AML at age 8. Recovery from a BMT from an HLA-mismatched-related donor was very
poor and he died of a severe viral infection soon after [114].
Data mining in large-scale genome analysis and expression proﬁle data from a panel of several hundred
cancer cell lines deposited at cBioportal (http://www.cbioportal.org/) reveals that many cancers have alterations
in UBE2T, in particular high frequencies of ampliﬁcations (Figure 4) [130]. Notably, UBE2T locates at 1q32.1,
and the gain of 1q is frequently observed in a variety of cancers [131]. Several recent studies investigated
UBE2T ampliﬁcations and UBE2T as a potential oncogene in different cancers. UBE2T is transcriptionally
up-regulated with increased protein levels observed in breast cancers of different histological subtypes, includ-
ing papillotubular, solid tubular, and scirrhous carcinoma [113]. The potential oncogenic function of elevated
UBE2T is likely to be polyubiquitination and subsequent proteasomal degradation of the E3 RING ligase
BRCA1 — a primary tumour suppressor associated with mammary carcinogenesis. In contrast, down-regulation
of UBE2T by RNAi stabilized BRCA1 and blocked cell growth in breast cancer cells. In vivo, it is unclear whether
UBE2T forms a direct, productive E2–E3 pair with BRCA1 or indirectly has an impact on the ubiquitin signal
by associating with an, as yet unidentiﬁed, E3 ligase.
Figure 4. UBE2T ampliﬁcations described in human cancer studies.
Graphic summary of frequencies of UBE2T alterations in cancers, mainly ampliﬁcations based on expression proﬁle data from a
panel of cancer cell lines deposited at cBioportal (http://www.cbioportal.org). Frequency of alteration is plotted against data
from individual cancer genomic studies. TCGA (The cancer genome atlas), MSKCC (Memorial Sloan-Kettering Cancer Center).
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Elevated expression of UBE2T is also associated with lung, gastric, prostate, and nasopharyngeal cancer
[132–135]. High UBE2T expression in gastric cancer tissue microarrays correlates with poor prognosis and was
proposed as a potential prognostic marker in gastric cancer progression. Ectopic expression of UBE2T in
gastric cancer cells promotes cell proliferation and induces epithelial–mesenchymal transition (EMT) by inhi-
biting the cell-to-cell adhesion factor E-cadherin, but elevating EMT-related factors N-cadherin, P-cadherin,
and vimentin levels [135]. Moreover, similar studies of prostate cancer showed that increased UBE2T expres-
sion promoted proliferation and was sufﬁcient to induce EMT of prostate cancer cells, as well as enhanced
tumour growth in prostate cancer xenograft mouse models and prostate cancer metastasis [133]. Finally, it was
demonstrated that UBE2T is highly expressed in nasopharyngeal carcinomas [134]. As in the aforementioned
studies, UBE2T overexpression promotes growth of nasopharyngeal carcinoma xenografts and metastasis.
Interestingly, elevated UBE2T expression in nasopharyngeal carcinomas activates the AKT/GSK3β/β-catenin
pathway, and inhibition of the pathway with the AKT inhibitor MK-2206 2HCL blocks the pro-metastatic
effect of UBE2T in nasopharyngeal cancers cells [134]. In summary, a common picture emerges from these
cancer studies, suggesting that increased UBE2T protein levels and presumed increase in UBE2T activity
promote cell transformation and cancer growth. UBE2T is less abundant in cells compared with other E2s, and
its expression is tightly controlled [136]. Hence, non-physiological high UBE2T levels may trigger ubiquitina-
tion of signal transduction modulators, such as the AKT/GSK3β/β-catenin pathway and EMT factors, thereby
either altering their activity or their cellular turnover by ubiquitin-target proteasomal degradation. Indeed,
β-catenin and vimentin homeostasis is regulated by protein turnover. Given that UBE2T has an essential role
in the FA DNA repair pathway, increased UBE2T may also trigger genome instability and subsequently cell
transformation. Overall, UBE2T is likely to exhibit diverse roles that are context dependent in different cancer
types. Efforts to identify UBE2T-speciﬁc substrates should be the ultimate goal in elucidating and dissecting the
molecular mechanism of UBE2T in carcinogenesis.
Disease association of UBE2L3 (UBCH7)
UBE2L3 (UBCH7) in autoimmune disease
In recent years, several genome-wide association studies (GWAS) identiﬁed polymorphisms in the genomic
locus of UBE2L3 that are associated with multiple autoimmune diseases. Haplotype analysis shows that the
UBE2L3 locus has a simple structure encompassing one linkage disequilibrium block covering the majority of
genetic variations and extending the full length of the gene locus (summarised in ref. [137]). Several single-
nucleotide polymorphisms (SNPs) describe risk alleles associated with systemic lupus erythematosus [138–140],
inﬂammatory bowel disease [141], Crohn’s disease [142], rheumatoid arthritis [143], celiac disease [144], psor-
iasis [145], diffuse cutaneous systemic sclerosis [146], and juvenile idiopathic arthritis [147]. Notably, the risk
allele rs5754217 shows signiﬁcant association with systemic lupus erythematosus and rheumatoid arthritis, sug-
gesting that both autoimmune rheumatological diseases may have UBE2L3 as a common susceptibility locus
[148]. A recent GWAS found that the UBE2L3 locus is associated with chronic hepatitis virus B infection in
Han Chinese patients, suggesting that UBE2L3 is required to clear hepatitis virus B infections. By employing
expression quantitative trait locus analysis, the majority of UBE2L3-associated SNPs that conferred disease risks
correlated with higher expression of UBE2L3. It is tempting to speculate that increased UBE2L3 expression and
elevated UBE2L3 activity may be causative of altered immune response pathways triggering autoimmune diseases.
The UBE2L3 enzyme consists of an UBC domain and retains several structural features of the generic UBC
fold. However, the catalytic cleft bears a histidine (His119) analogous to the acidic residue in the α3–α4 loop
(D117 in UBE2D1) that orients the incoming substrate lysine. Early biochemical and structural studies describe
UBE2L3 as predominantly functioning with HECT E3s [149–151]. A landmark study that compared
E3-independent E2∼Ub reactivity proﬁles discovered UBE2L3∼Ub to be sensitive exclusively to thiol (cysteine)
acceptors, whereas UBE2D3∼Ub could ofﬂoad ubiquitin to both free lysines and cysteines [152]. Furthermore,
the intrinsic property of UBE2L3 was unaffected by the presence of RING E3s. These data deﬁne UBE2L3 as
primarily co-operating with HECT or RBR E3 ligases (RING1-BRcat-Rcat E3 ligases), wherein the E2∼Ub
intermediate ofﬂoads ubiquitin onto the E3 catalytic cysteine rather than a substrate lysine.
UBE2L3 surface proﬁling reveals hot-spot residues (Lys9 in α1, Phe63 in the β2–β3 loop, and Glu93, Lys96,
and Lys100 in the 310-to-α2 loop) that drive HECT E3 interactions and consequent ubiquitination events
[18,153]. Interestingly, the same surface is exploited by the pathogenic Shigella effector kinase, OspG, for
binding the UBE2L3∼Ub intermediate [154,155]. This interaction impedes productive E2–E3 interactions and
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downstream ubiquitin signals during innate immune responses while concomitantly enhancing OspG kinase
activity that abets pathogenic infection. Recent structure–function studies suggest that HECT/RBR E3s do not
require a closed E2∼Ub conformation to promote ubiquitination [61–63]. In the case of UBE2L3, the RBR
region of HHARI (human homologue of Ariadne) binds tightly with the E2 (roughly 200 nM Kd) via an endo-
thermic process [156]. Similar analysis with an activated Parkin E3 species reveals a strong binding with only
the UBE2L3∼Ub intermediate (roughly 900 nM Kd) [157]. Furthermore, kinetic analysis of the interaction
between UBE2L3 and the HECT E3 E6-AP (human papillomavirus E6-associated protein) reveals the presence
of an, as yet unidentiﬁed, E2∼Ub docking site that is required for E3∼Ub formation, and is distinct from the
canonical E3–UBE2L3 interface [158]. Taken together, we are as yet unable to mechanistically deﬁne how
UBE2L3 undertakes E3∼Ub loading as well as inducing polyubiquitination.
The intrinsic catalytic property of UBE2L3 restricts its functional alliance to a subset of E3s, namely the
HECT-like E3 ligases and the specialized class of RBR E3s [18,152]. Nevertheless, deep proteomics of in vivo
protein copy numbers indicate UBE2L3 as one of the most abundant E2s in mammalian cell lines [136].
Importantly, UBE2L3 can form productive E2–E3 pairs with the disease-associated E3 ligase LUBAC in vitro
[159,160]. The 600 kDa RBR ligase complex LUBAC (linear ubiquitin chain assembly complex) associates with
UBE2L3 and speciﬁcally forms linear (Met1-linked) ubiquitin chains in vitro. LUBAC is composed of
HOIL-1L-interacting protein (HOIP), haem-oxidized IRP2 ubiquitin ligase-1 (HOIL-1L), and Sharpin
(SHANK-associated RH domain interaction protein in postsynaptic density). Both HOIP and HOIL-1L pro-
teins bear the multidomain signature seen in RBR E3s, but HOIP is thought to be the critical catalytic subunit
Figure 5. LUBAC and UBE2L3 regulate NF-κB response.
(A) Cytokine/receptor-mediated activation of LUBAC/UBE2L3 triggers linear (Met1) polyubiquitination of NEMO required for IKK
kinase activation. IKK phosphorylates the NF-κB sequestration protein IκBα that is then recognized by SCF/β-TrCP ligase for
Lys48 polyubiquitination and subsequent degradation by the proteasome. Released NF-κB translocates to the nucleus to
transactivate NF-κB response genes. (B) Model for hyperactivation (indicated by red arrows) of the NF-κB pathway in patients
carrying UBE2L3 risk alleles associated with autoimmune diseases. UBE2L3 SNP rs140490 correlates with increased levels of
UBE2L3 protein, causing enhanced LUBAC signalling, accelerated IκBα degradation, and hyperactive NF-κB response.
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of LUBAC. The E3 activity of HOIP is latent and is stimulated by heterodimer complex formation with either
HOIL-1L or Sharpin. Several lines of genetic evidence suggest an important regulatory role of LUBAC and
Met1-chain assembly in immune response signalling cascades (Figure 5A). LUBAC was shown to be critical for
the efﬁcient activation of NF-κB signalling, in part, by linear ubiquitination of NEMO, which is required to
activate IKK kinase. IKK phosphorylates the NF-κB sequestration protein IκBα and triggers its degradation by
the ubiquitin–proteasome system, releasing NF-κB during the initial phase of the NF-κB response.
Importantly, recent work suggests that LUBAC participates in TNF receptor-mediated and genotoxin-induced
apoptotic pathways by regulating death-promoting complexes in an inhibitory fashion [161–164]. Bi-allelic
mutations of HOIL-1L were recently shown to underlie severe autoinﬂammation, immunodeﬁciency, and amy-
lopectinosis [165] in human patients. HOIL-1L-deﬁcient ﬁbroblasts, and B-cells derived from patients, display
impaired NF-κB activation in response to TLR agonists (TNF and IL-1β) and CD40L, respectively. In contrast,
HOIL-1L-deﬁcient monocytes are hyper-responsive to IL-1β, which probably accounts for the autoinﬂamma-
tory phenotype in these patients. Recently, a patient with multiorgan autoinﬂammation and combined
immunodeﬁciency was reported to bear a homozygous mutation in HOIP [166]. The cellular and clinical phe-
notypes largely overlap with those of HOIL-1L-deﬁcient patients. In summary, there is overwhelming evidence
that assembly and activity of LUBAC is required in a cell- and organ-dependent manner for various signalling
pathways governing inﬂammation and immunity.
Given that UBE2L3 and LUBAC are both associated with autoimmune syndromes, an open question
remained, until recently, as to whether UBE2L3 is a physiological E2 for LUBAC. Work by Lewis et al. [137]
provided some insights into the underlying mechanism of UBE2L3 polymorphism and LUBAC function in sys-
temic lupus erythematosus (Figure 5B). GWAS of systemic lupus erythematosus identiﬁed rs140490 as the
most strongly associated SNP, which is located downstream of the promoter region of UBE2L3. Messenger
RNA for UBE2L3 is increased in CD19+ B cells and CD4+ T cells isolated from peripheral blood of individuals
with rs140490 genotype. However, rs140490 has increased UBE2L3 protein levels in only CD19+ B cells. Using
NF-κB luciferase reporter cell lines, overexpression of UBE2L3 is not sufﬁcient to increase basal NF-κB activa-
tion. However, co-expression of UBE2L3 with HOIP–HOIL-1L or HOIP–Sharpin triggers substantial
up-regulation of NF-κB activity, particularly at the late phase of the biphasic NF-κB response. The effect is spe-
ciﬁc for UBE2L3; other E2s can form productive E2–E3 pairs with LUBAC in vitro, such as UBE2D1,
UBE2D2, UBE2D3, or UBE2L6, but they do not affect NF-κB activation in the context of LUBAC subcom-
plexes. Down-regulation of UBE2L3, by siRNA, impairs phosphorylation and degradation of IκBα, similar to
that observed in LUBAC-deﬁcient cells [159,167–169]. Hence, UBE2L3 is likely to be the preferred E2 for
LUBAC-mediated regulation of the NF-κB response. Ex vivo cell experiments demonstrate that the UBE2L3/
rs140490 genotype increases basal and stimulated nuclear translocation of NF-κB in primary human B cells
and monocytes (Figure 5B). Moreover, analysis of B-cell subsets from human blood samples reveals that the
UBE2L3 risk allele is speciﬁcally associated with increased levels of UBE2L3 in plasmablasts and plasma cells of
systemic lupus erythematosus-affected patients, but not in healthy individuals. Taken together, these data
suggest that increased abundance of UBE2L3 and an up-regulated NF-κB response may play a causative role in
abnormal B-cell differentiation and proliferation in autoimmune diseases.
Function of UBE2L3–HOIP in cancer
Hyperactivation of the NF-κB pathway is implicated in several blood cancers [170]. Active B cell-like (ABC)
diffuse large B cell lymphomas (DLBCLs) are characterized by the constitutively activated NF-κB pathway,
commonly due to gain-of-function mutations in the B-cell receptor and MYD88 pathways. Recently, screening
biopsies of ABC-DLBCL have identiﬁed rare germline SNPs in the HOIP gene [171]. These SNPs increase the
binding of HOIP to HOIL-1L resulting in an increased HOIP activity that contributes to NF-κB hyperactiva-
tion in ABC-DLBCL cells. It will be interesting to examine whether UBE2L3 is elevated in ABC-DLBCL cells
and whether UBE2L3 is, as proposed by Lewis et al., a rate limiting factor for LUBAC activity. Hence, UBE2L3
might be a potential therapeutic target to treat SLE and B-cell lymphomas that are characterized by LUBAC
hyperactivation and constitutive NF-κB signalling.
Functional association of UBE2L3 with Parkinson’s disease
Genotype and linkage analysis revealed that mutations in the PARK2 gene, encoding Parkin RBR E3 ligase, are
the most frequent cause of sporadic early- and late-onset Parkinson’s disease (PD) cases [172,173]. In addition,
PARK2 was described as a putative tumour suppressor gene [174]. Parkin is thought to have an essential
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neuroprotective function by regulating mitophagy required for mitochondrial homeostasis and quality control.
However, the identity of the cognate E2 that associates with Parkin in mitophagy and PD is less well deﬁned.
Parkin E3 ligase activity is auto-inhibited by the N-terminal UBL domain, which obscures the catalytic inter-
action between Parkin and the ubiquitin-loaded E2 [175–178]. Parkin’s auto-inhibited state is relieved, and E3
ligase activated, by a dual PINK1 kinase-mediated phosphorylation event that involves phosphorylation of a
crucial residue Ser65 on the UBL domain as well as binding of phosphor-Ser65 ubiquitin [179–183].
Subsequently, PINK1-activated Parkin allows the interaction with different ubiquitin-loaded E2s, including
UBE2L3, to trigger and amplify ubiquitin signals at damaged mitochondria. Recent studies suggest a potential
role of UBE2L3 in Parkin-dependent mitophagy [184,185]. Initial evidence came from in situ hybridization
studies in rat brain tissues that indicate similar pattern and developmental changes in the expression of Parkin
and UBE2L3 [186]. UBE2L3 is translocated to depolarized mitochondria dependent on active Parkin [184].
siRNA-mediated knockdown of UBE2L3 does not interfere with Parkin translocation, but impairs
Parkin-dependent clearance of depolarized mitochondria [184,185]. Interestingly, only the simultaneous knock-
down of UBE2L3, UBE2N, and UBE2D2/3 reduces ubiquitination of proteins of depolarized mitochondria
[184]. Therefore, Parkin apparently employs different E2 enzymes to generate distinct ubiquitin chain signals
that mediate efﬁcient mitophagy. The apparent redundant functions of UBE2L3 with other E2s may explain
the current lack of any genetic association of UBE2L3 gene alterations with PD.
Future perspectives
Our current understanding of E2 function includes substantial insights into the mechanisms common to all E2s.
This ﬁeld is now entering a phase of uncovering the differences between the enzymes that position each E2 in a
given physiological context. This may also provide us with a framework to explain pathological functions of E2s
associated with diseases. Indeed, the spectrum of pathologies and diseases associated with E2s is broad, ranging
from immunological disorders and neurological syndromes (e.g. UBE2A [187]) to cancer, and undoubtedly,
further involvement of E2s in other diseases will be discovered. The majority of E2s are linked with cancer of
many different origins. The functional roles of several E2s in breast carcinogenesis have been described (reviewed
in ref. [188]). For example, UBE2N is an emerging key player in various cancers, and the recently developed small
compound inhibitor NSC697923 targeting UBE2N inhibits proliferation and survival of neuroblastoma and
DLBCL cells. With the advent of enzymatic tools for trapping various states of E2 intermediates, there are now
more opportunities to address the unique properties of E2s in different biological contexts and, importantly, to
dissect disease pathways [189,190]. Certainly, this will pave the way to exploit E2s in therapeutic contexts, in par-
ticular by developing new strategies to target individual E2s or speciﬁc interactions of E2–E3 pairs.
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